We’re very pleased to have achieved this important milestone in our efforts to secure coverage of TEGSEDI for those living with the polyneuropathy of hATTR in Canada," said Jared Rhines, senior vice president, Americas, and general manager at Akcea Therapeutics Canada. "This achievement underscores the data supporting TEGSEDI and the critical unmet need for these patients living with this progressive disease. We appreciate the pCPA team’s thorough review and response, which lays the path forward for our discussions with the provinces, territories and federal agencies. We understand that these are challenging times with COVID-19 and we look forward to productive discussions at the earliest, appropriate, time.

For full article visit: https://ir.akceatx.com/2020-05-13-Akcea-Therapeutics-Canada-Confirms-Letter-of-Intent-with-Pan-Canadian-Pharmaceutical-Alliance-for-TEGSEDI-TM-inotersen-injection